Kimelman & Baird’s Idexx Laboratories IDXX Stock Holding History

Kimelman & Baird’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,500	Closed	-$327K	–	108
2018 Q2	$327K	Buy	+1,500	New	+$309K	0.04%	87
2017 Q4	$469K	Hold	3,000	–	–	0.07%	83
2017 Q3	$466K	Hold	3,000	–	–	0.07%	82
2017 Q2	$484K	Sell	3,000 -1,000	-25%	-$162K	0.07%	83
2017 Q1	$618K	Sell	4,000 -1,000	-20%	-$138K	0.09%	75
2016 Q4	$586K	Buy	+5,000	New	+$571K	0.1%	71

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Kimelman & Baird's IDXX Position: Q3 2018 in Review

Kimelman & Baird sold out of Idexx Laboratories (IDXX) in Q3 2018, closing a stake of 1,500 shares — an estimated $327K sold.

Kimelman & Baird first reported a position in IDXX in Q4 2016 and held it in 6 quarters. The position peaked at $618K in Q1 2017. 698 funds tracked by Wall St. Rank hold IDXX as of Q3 2018.

Kimelman & Baird reported no remaining Idexx Laboratories position as of Q3 2018 after selling out during the quarter.
Kimelman & Baird sold 1,500 Idexx Laboratories shares in Q3 2018, an estimated $327K.
Kimelman & Baird first reported a position in Idexx Laboratories in Q4 2016 and held it in 6 quarters.
Kimelman & Baird's Idexx Laboratories position peaked at $618K in Q1 2017.
698 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2018.

Based on Kimelman & Baird's 13F filing for Q3 2018, filed 30 Jan 2019.